Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2013 by Boryung Pharmaceutical Co., Ltd.
Recruitment status was  Recruiting
Gachon University Gil Medical Center
The Catholic University of Korea
Gyungbook national university hospital
Daegu Catholic University Medical Center
Wonkwang university Hospital
Wonju Severance Christian Hospital
Korea University Guro Hospital
DongGuk University
Yeungnam University
Chonnam National University Hospital
Cheil General Hospital and Women’s Healthcare Center
Chungnam National University
Asan Medical Center
Seoul National University Bundang Hospital
Inha University Hospital
Seoul National University Hospital
Inje University
Samsung Medical Center
Busan university Yangsan Hospital
Soon Chun Hyang University
Catholic University of Korea St. Paul's Hospital
Hallym University Medical Center Kang-Dong
Jeju National University Hospital
Hanyang University Seoul Hoapital
Kangbuk Samsung Hospital
Information provided by (Responsible Party):
Boryung Pharmaceutical Co., Ltd Identifier:
First received: January 24, 2012
Last updated: March 26, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)